Doxrubicine

Bladder cancer SW780 and T24 cells were cultured in DMEM medium containing 10% (v/v) fetal bovine serum and 1% penicillin-streptomycin (Life technology, United States) at 37°C in 5% CO₂ humidified incubator. MTT and Doxrubicine (DOX) were obtained from Sigma, USA. Transwell plates were from Corning Incorporated, United States. Annexin V-FITC kit was purchased from BD Pharmingen, United States. NF-κB, NF-κB p65 (p-NF-κB), MDM2, Phospho-MDM2 (p-MDM2), p53, p21, Bcl-2, and PARP were purchased from Cell signaling technology, United States. Alanine transaminase (ALT), Creatine kinase (CK), and aspartate transaminase (AST) kits were obtained from Stanbio, United States. NF-κB inhibitor (SC75741) was purchased from Selleck, United States.

Viridiflorol, Doxrubicine, Temozolomide and dimethylsulphoxide (DMSO) were purchased from Sigma Chemical Co. (St. Louis, MO, USA) and dissolved in DMSO (final volume during cell manipulations were kept ≤ 0.1%) according to the manufacturer’s requirements. A real-time Glo MT Cell Viability Assay was purchased from Promega, Co. (Madison, WI, USA. Cat. G9711). Penicillin streptomycin, trypsin, phosphate buffer saline (PBS), DMEM media and fetal bovine serum (FBS) were purchased from Gibco (Grand Island, NY, USA).